REV-ERB agonist

SR-9009 (Stenabolic)

SR-9009 (Stenabolic) is a REV-ERB agonist named as an example under the metabolic modulators class of the 2026 WADA Prohibited List, and the app lists a half-life of about 4 hours.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

SR-9009 (Stenabolic) after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.

Drawn from the half-life in the app's model, ~4 h. The model's figures

1

Overview

SR-9009, sold under the name Stenabolic, is a REV-ERB agonist, a compound that activates the nuclear receptors REV-ERBα and REV-ERBβ.2,3 Solt and colleagues at The Scripps Research Institute described SR9009 and the related compound SR9011 in Nature in 2012, as "potent synthetic REV-ERB agonists with in vivo activity".2 The app lists SR-9009 under the category SARM with the sub-category Rev-ErbA agonist, and its notes say it is not a selective androgen receptor modulator. A 2017 JAMA analysis of 44 products sold on the internet as selective androgen receptor modulators reported that 17 (39%) contained another unapproved drug, a group that included the Rev-ErbA agonist SR9009.3 The findings the sources report come from cells, mice, human liver microsomes and laboratory analysis of products, and no controlled trial in people was identified. The app grades the evidence for SR-9009 as emerging.

2

How it works

Solt and colleagues reported in HEK293 cell assays that SR9009 repressed activity with IC50 values of 670 nM at REV-ERBα and 800 nM at REV-ERBβ.2 They also report direct binding of SR9009 to REV-ERBα with a Kd of 800 nM, and write that "Neither compound exhibited activity at other nuclear receptors".2 In mice kept in constant darkness, "administration of a single dose of either REV-ERB agonist resulted in loss of locomotor activity during the subject dark phase".2 Under a 12-hour light and 12-hour dark cycle the authors instead "noted a 1–3 h delay in the onset of nocturnal locomotor activity".2 Woldt and colleagues, at Institut Pasteur de Lille, reported in Nature Medicine in 2013 that Rev-erb-α "is highly expressed in oxidative skeletal muscle" and that its deficiency in muscle led to reduced mitochondrial content and compromised exercise capacity in mice.4 In that paper, incubation of C2C12 muscle cells with two REV-ERB agonists increased the number of total and active mitochondria, and SR9009-treated mice ran longer than vehicle-treated mice.4

Deeper analysis: Solt and colleagues, Nature 2012

Solt and colleagues tested SR9009 and SR9011 in cell assays, in mouse tissue explants and in mice, with the mouse studies given by intraperitoneal (i.p.) injection.2 In the obesity experiment, 20-week-old C57BL6 mice weighing on average 41 g, kept on a high fat diet for 14 weeks, received SR9009 at 100 mg/kg i.p. twice daily for 30 days, with vehicle-treated mice as the comparator and n=6–10 mice per group in the figure legend.2 The authors report that "weight loss of SR9009-treated animals was 60% greater" than in vehicle-treated controls, with a 12% decrease in plasma triglycerides and a 47% decrease in plasma total cholesterol.2 Plasma non-esterified fatty acids were reduced by 23% and plasma glucose by 19%, and the paper describes the 35% fall in plasma insulin as "a trend".2 The same paragraph states that "there was no significant difference in the food intake of SR9009 and vehicle treated animals" and that the handling and injections themselves "caused weight loss in vehicle-treated controls", so the 60% figure is a comparison against controls that were also losing weight.2 In ob/ob mice, a leptin-deficient strain, 12 days of SR9009 "suppressed the degree of weight gain" with "no significant alterations in glucose or insulin tolerance".2 Much of the circadian and whole-body metabolic work in the paper used SR9011, and for SR9009 the authors write that treatment "resulted in similar effects on gene expression" and that similar effects in fat tissue were seen in "data not shown".2 On safety in mice the authors write that they "observed no overt toxicity when we examined complete blood counts".2 The authors conclude that the compounds "may hold utility in the treatment of sleep disorders as well as metabolic diseases", a statement about mice that is not a result in people.2 Funding came from National Institutes of Health grants and the Howard Hughes Medical Institute, and the authors "declare no competing financial interests".2 The author contributions list the compounds' synthesis and the pharmacokinetic analysis among the authors' tasks, and the sections of the paper read contain no separate limitations statement.2

Deeper analysis: Woldt and colleagues, Nature Medicine 2013

Woldt and colleagues studied Rev-erb-α in skeletal muscle with muscle-specific deficiency, knock-down, over-expression and a pharmacological arm using SR9009.4 In the SR9009 arm, mice received 100 mpk i.p. for 30 days and were compared with vehicle-treated mice in an endurance exercise test, with n = 6 per group.4 The authors report that the treated mice "ran significantly longer both in time and distance"; the text read gives the result as a figure panel, so the size of the difference is not quoted here.4 The paper's funding statement lists a Marie Curie International Reintegration Grant, the European Commission (FP7) consortium Eurhythdia, Région Nord Pas-de-Calais/FEDER, an unrestricted ITMO/Astra Zeneca grant, a joint Société Francophone du Diabète (SFD)/MSD research fellowship, a European Foundation for the Study of Diabetes research grant, National Institutes of Health grants and a Netherlands Organization for Scientific Research VICI grant, and a conflict statement that "The authors declare no competing financial interests".4 The sections read contain no separate limitations statement for the SR9009 experiment, which the paper describes in a single paragraph.4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
2%
Typical dose
20–30 mg/day
Route
Oral / SubQ
Time to peak
~1 h

The second column of the table holds the app's own figures, and the third holds what the sources read report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~4 hNo half-life figure for SR9009 appears in the sources read; after a single injection in mice, Solt and colleagues write that normal activity returned the next circadian cycle, "consistent with clearance of the drugs in less than 24h"2
Bioavailability2%No bioavailability figure appears in the sources read; Solt and colleagues describe "reasonable plasma exposure" of the compounds in mice2
Time to peak~1 hNo time-to-peak figure appears in the sources read
Duration of activity~8 hNo duration figure appears in the sources read
RoutesOral, SubQSolt and colleagues and Woldt and colleagues gave SR9009 to mice by i.p. injection; the products analysed by Van Wagoner and colleagues were listed in capsules for the SR9009 product2,4,3

The sources read do not report a half-life or bioavailability for SR9009 in people, so the app's 4 hours and 2% stand here without a sourced figure beside them.

Metabolism in human liver microsomes

Geldof and colleagues, at the Doping Control Laboratory of Ghent University, reported in the International Journal of Molecular Sciences in 2016 that "via human liver microsomal metabolic assays, eight metabolites were detected for SR9009".5 Mazzarino and colleagues, at the anti-doping laboratory of the Federazione Medico Sportiva Italiana in Rome, reported in Drug Testing and Analysis in 2018 that SR9009 "was biotransformed to 13 metabolites by CYP3A4, CYP3A5, CYP2C19, and CYP2D6 isoenzymes".6 In their in vitro work, "the de-alkylated metabolites being the most abundant" and no significant difference was measured between female and male microsomes.6 They also report significant differences with the CYP2D6 or CYP2C19 allelic variants, significant alterations in the presence of ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine, and moderate variation with fluconazole, itraconazole, gestodene and levonorgestrel.6 These are laboratory findings with microsomes and isolated enzymes, and Geldof and colleagues write that "extrapolation from these in vitro studies to the more complex human situation is difficult".5 Geldof and colleagues add that in vitro techniques do not cover "other pharmacokinetic processes, including absorption, distribution and excretion".5

4

Human studies

No controlled trial of SR-9009 in people was identified in PubMed (the 20 of 58 records listed for "SR9009 Rev-erb agonist") or in ClinicalTrials.gov searches for "SR9009" and "REV-ERB agonist". Van Wagoner and colleagues wrote in JAMA in 2017 that "Preclinical studies have occurred for SR9009, but no human trials".3 Geldof and colleagues wrote in 2016 that "no pharmaceutical preparations are available yet".5 Geldof and colleagues also refer to human excretion studies of SR9009 and SR9011 by Sobolevsky and colleagues, in which metabolite SR09-5 was described as a major metabolite; that work was not among the sources read.5

The table lists the two studies that used human-derived material. Nobody was given SR9009 in either.

Table 4.1Human studies2 rows
Study and yearDesignPeopleDose and lengthMain result
Geldof and colleagues, Int J Mol Sci 20165In vitro incubation with human liver microsomes, then retrospective analysis of routine doping control urine; financial support from the Partnership for Clean Competition, no conflict of interest declared5No participants dosed; pooled microsomes from 20–30 donors and 1511 routine doping control urine samples5Not applicable (incubation; no dose to people)5Eight SR9009 metabolites detected in vitro; "neither the parent compound nor the metabolites could be detected in routine urine samples"5
Mazzarino and colleagues, Drug Test Anal 20186In vitro study with human liver microsomes and cytochrome P450 isoforms; grant from the Italian Department of Health6No participants dosed6Not applicable (in vitro)613 metabolites; significant alterations with CYP2D6 or CYP2C19 variants and in the presence of ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine; moderate variation with fluconazole, itraconazole, gestodene and levonorgestrel; no significant alterations between female and male6

Deeper analysis: Geldof and colleagues, International Journal of Molecular Sciences 2016

Geldof and colleagues purchased "a black market product sold as a performance-enhancing product and labeled to contain SR9009" over the Internet and confirmed that it contained the compound.5 They then incubated SR9009 and SR9011 with human liver microsomes, identified metabolites by liquid chromatography and high resolution mass spectrometry, and applied retrospective analysis to 1511 doping control samples.5 The result for the urine samples was null: "Although misuse of SR9009 and SR9011 could not be demonstrated in our study", the authors recommend adding both compounds to screening methods.5 The authors state that the microsome work has limits: "The lack of an intact biological system can hamper the extrapolation of in vitro results to the human situation".5 Funding was from the Partnership for Clean Competition, and the paper states that "The founding sponsors had no role in the design of the study".5 The PubMed record for Mazzarino and colleagues holds a summary but no full text, so its funding statement beyond the listed grant, its conflict statement and its limitations are not available here.6

5

Doses reported in studies and on labels

The sources read give no dose of SR9009 in people from a trial; the amounts they report are doses in mice and the strength claimed on an internet product label.

Table 5.1Doses reported in studies and on labels5 rows
SourceSetting and routeAmount reportedDuration and nComparator
Solt and colleagues, Nature 20122Diet-induced obese C57BL6 mice, i.p. injection100 mg/kg twice daily30 days; n=6–10 mice in the figure legendVehicle-treated mice2
Solt and colleagues, Nature 2012, gene expression experiment2Male C57BL6 mice aged 8–10 weeks, i.p. injection100 mg/kg, a single doseSingle dose; groups of n=6SR9011 given in the same experiment2
Woldt and colleagues, Nature Medicine 20134Mice, i.p. injection; endurance exercise test100 mpk (mg/kg)30 days; n = 6 per groupVehicle-treated mice4
Van Wagoner and colleagues, JAMA 2017: label of one internet product3Capsules; label reads "Not for human consumption; Research use only"20 mg of SR9009 per capsule (label claim)40 capsules in the product; n=1 productAnalysis listed 1-5 mg of androstatrienedione per capsule instead3
The app's figureOral or SubQ, per day20–30 mg/dayNot statedNot applicable

Deeper analysis: Van Wagoner and colleagues, JAMA 2017

Van Wagoner and colleagues, from the Sports Medicine Research and Testing Laboratory in Salt Lake City, the US Anti-Doping Agency and other centres, searched the web from February 18 to March 25, 2016, bought 44 products marketed as selective androgen receptor modulators, and analysed them from April to August 2016 with World Anti-Doping Association-approved procedures.3 Of the 44 products, 23 (52%) contained a selective androgen receptor modulator, 17 (39%) contained another unapproved drug that included SR9009, no active compound was detected in 4 (9%), and the amount on the label matched the analysis in 18 (41%).3 The table in the paper lists one product whose label claimed 20 mg of SR9009 per capsule, placed in the group where the labelled compound was not found and unlisted active compounds were found.3 The authors state that "Neither the efficacy nor the safety of these investigational drugs has been demonstrated".3 Their stated limitations include that "all possible internet sites were not searched" and that "The results apply only to the products purchased".3 The project was partly funded by a Defense Health Program grant through the Henry M. Jackson Foundation to the US Anti-Doping Agency, and the foundation "had no role in the design and conduct of the study".3 One author, Dr Bhasin, disclosed investigator-initiated research grants from companies including Abbott, Ligand, Regeneron, Novartis, AbbVie, Merck and Takeda Pharmaceuticals, consulting fees from AbbVie, Novartis, Sanofi and Regeneron, and an equity interest in FPT LLC.3

6

Side effects reported

No adverse event data from people given SR9009 were identified in the sources read. In mice, Solt and colleagues reported a loss of locomotor activity during the subject dark phase after a single dose in constant darkness, and they state that this "was not due to toxicity since the complete loss of locomotor activity was not observed in an identical experiment using L:D".2 In the same paper, they report no overt toxicity on complete blood counts in mice.2 Geldof and colleagues refer to SR9009 and SR9011 as "these potentially harmful compounds", without giving a specific harm.5 Van Wagoner and colleagues write that the efficacy and safety of the investigational drugs in the products they tested "has not been demonstrated".3

7

Bloodwork and markers

Sources in this part

  1. 2Solt et al., 2012

The app lists total testosterone, lipids and liver enzymes as markers to monitor for SR-9009. In mice on a high fat diet given SR9009, Solt and colleagues reported lower fasting plasma triglycerides, total cholesterol, non-esterified fatty acids and glucose than in vehicle-treated mice.2 The sources read report no total testosterone or liver enzyme result for SR9009 in mice or in people. The sources read report no lipid result for SR9009 in people.

8

Regulatory and anti-doping status

The 2026 WADA Prohibited List names "Rev-erbɑ agonists, e.g. SR9009, SR9011" under S4.4, metabolic modulators, within the class of hormone and metabolic modulators prohibited at all times, in and out of competition.1 The list states that substances in classes S4.3 and S4.4 are non-Specified Substances.1 In 2016 Geldof and colleagues wrote that the compounds were, "Even though not explicitly mentioned on the Prohibited List", "indirectly prohibited as non-approved substances (Class S0)".5 In 2017 Van Wagoner and colleagues wrote that the growth hormone secretagogues, PPAR-δ agonists and Rev-ErbA agonists in the products they tested are "all of which are recognized by WADA as banned substances".3 The same authors write that "None of the tested compounds meets the definition of a dietary supplement", and that nearly half the products were marketed as dietary supplements.3 No approval document or label for SR9009 from the US FDA, the EMA or the TGA was identified in the sources read.

9

What is not known

The sources read give no half-life, bioavailability, time to peak or duration for SR9009 in people, so the app's figures of 4 hours, 2%, 1 hour and 8 hours stand without a sourced figure beside them. No controlled trial of SR9009 in people was identified in PubMed or ClinicalTrials.gov, and the sources read report no human efficacy or safety outcome. The app's note that SR-9009 is non-suppressive to endogenous hormone production has no figure or statement behind it in the sources read. The in vitro alterations Mazzarino and colleagues report in the presence of ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine have not been matched to any human study in the sources read.6 In the JAMA analysis, the one product whose label claimed SR9009 listed a different compound on analysis, and the authors note that the sample is limited to a single point in purchase time.3

What is SR-9009?

SR-9009, also called Stenabolic, is a REV-ERB agonist that activates the nuclear receptors REV-ERBα and REV-ERBβ.2,3 Solt and colleagues at The Scripps Research Institute described it in Nature in 2012.2

Is SR-9009 a SARM?

The app's notes say SR-9009 is not a selective androgen receptor modulator, and Van Wagoner and colleagues list it as a Rev-ErbA agonist separate from the selective androgen receptor modulators they found in products. Solt and colleagues report that SR9009 and SR9011 showed no activity at other nuclear receptors in their assays.2

What is the half-life of SR-9009?

The app lists a half-life of about 4 hours, and the sources read give no half-life figure for SR9009. After a single injection in mice, Solt and colleagues describe "clearance of the drugs in less than 24h".2

What is the bioavailability of SR-9009?

The app lists 2%, and the sources read give no bioavailability figure for SR9009.

Is SR-9009 banned by WADA?

The 2026 WADA Prohibited List names Rev-erbɑ agonists, "e.g. SR9009, SR9011", under S4.4 metabolic modulators, prohibited at all times.1 Geldof and colleagues reported no SR9009 or its metabolites in 1511 routine doping control samples in 2016.5

Has SR-9009 been tested in people?

No controlled trial of SR-9009 in people was identified in PubMed or ClinicalTrials.gov. Van Wagoner and colleagues wrote in 2017 that "Preclinical studies have occurred for SR9009, but no human trials".3

What did SR-9009 do in mouse studies?

In mice, SR9009 given at 100 mg/kg i.p. for 30 days was followed by longer running in an endurance test than vehicle, reported by Woldt and colleagues in 2013 with n = 6 per group.4 In diet-induced obese mice, Solt and colleagues reported weight loss 60% greater than in vehicle-treated controls, who also lost weight from the stress of handling and twice-daily injections, and a 47% decrease in plasma total cholesterol.2 These are mouse results, and the sources read give no matching result in people.

Which enzymes metabolise SR-9009?

In human liver microsomes, Mazzarino and colleagues reported that CYP3A4, CYP3A5, CYP2C19 and CYP2D6 isoenzymes biotransformed SR9009 to 13 metabolites.6 This is an in vitro result and not a result in people given the compound.5

Do products sold as SR-9009 contain it?

Van Wagoner and colleagues analysed one product labelled as 20 mg of SR9009 per capsule and its analysis listed 1-5 mg of androstatrienedione per capsule instead.3 The same paper reports that 17 of the 44 products (39%) contained another unapproved drug, including the Rev-ErbA agonist SR9009.3 Geldof and colleagues, in 2016, confirmed SR9009 in a different black market product they purchased over the Internet.5

12

References

  1. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  2. Solt LA, et al. Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists. Nature 2012. PMID 22460951
  3. Van Wagoner RM, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017. PMID 29183075
  4. Woldt E, et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med 2013. PMID 23852339
  5. Geldof L, et al. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. Int J Mol Sci 2016. PMID 27706103
  6. Mazzarino M, et al. A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009. Drug Test Anal 2018. PMID 30395700